MARKET

HALO

HALO

Halozyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

47.81
-0.66
-1.36%
Pre Market: 47.81 0 0.00% 08:51 05/06 EDT
OPEN
48.21
PREV CLOSE
48.47
HIGH
48.89
LOW
47.46
VOLUME
103
TURNOVER
--
52 WEEK HIGH
56.40
52 WEEK LOW
22.11
MARKET CAP
6.85B
P/E (TTM)
53.21
1D
5D
1M
3M
1Y
5Y
Halo Collective Announces April Sales
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
CNW Group - CND · 17h ago
Halo Announces At-The-Market Equity Financing Program
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN OR INTO THE UNITED STATES/
CNW Group - CND · 22h ago
8-K: HALOZYME THERAPEUTICS, INC.
(EDGAR Online via COMTEX) -- false000115903600011590362021-05-012021-05-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 2d ago
Insider Trends: Insider at Halozyme Therapeutics Reports Option Conversion in Mist of 90-Day Buying Trend
MT Newswires · 2d ago
Halozyme to Present at BofA Securities 2021 Virtual Health Care Conference
SAN DIEGO, April 29, 2021 /PRNewswire via COMTEX/ -- SAN DIEGO, April 29, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced...
PR Newswire - PRF · 6d ago
Red Light Holland and Halo Collective Create Red Light Oregon, Inc. - Forwarding Intentions to Enter Oregon Medicinal Psychedelic Market
Toronto, Ontario, Apr 27, 2021 (Newsfile Corp via COMTEX) -- Toronto, Ontario--(Newsfile Corp. - April 27, 2021) - Further to the joint press release dated...
Newsfile Corp · 04/27 13:22
Is HALO Stock A Buy or Sell?
Insider Monkey · 04/22 20:19
IBD 50 Stocks To Watch: A Biotech Stock Angling For An Earnings Halo
Up 21% in April, IBD 50 stock to watch Halozyme is climbing towards a buy point, as analysts project a 900% EPS gain in its first quarter.
Investor's Business Daily · 04/22 20:10
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HALO. Analyze the recent business situations of Halozyme through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HALO stock price target is 49.20 with a high estimate of 64.00 and a low estimate of 17.00.
EPS
Institutional Holdings
Institutions: 450
Institutional Holdings: 150.79M
% Owned: 105.23%
Shares Outstanding: 143.30M
TypeInstitutionsShares
Increased
105
16.38M
New
100
4.23M
Decreased
105
16.85M
Sold Out
25
2.18M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.92%
Pharmaceuticals & Medical Research
+0.20%
Key Executives
Chairman/Independent Director
Connie Matsui
President/Chief Executive Officer/Director
Helen Torley
Chief Financial Officer/Senior Vice President
Elaine Sun
Senior Vice President/Chief Technology Officer
Michael LaBarre
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
Masaru Matsuda
Independent Director
Jean-Pierre Bizzari
Independent Director
Bernadette Connaughton
Independent Director
James Daly
Independent Director
Jeffrey Henderson
Independent Director
Matthew Posard
No Data
  • All
  • Financials
  • Insiders
More
About HALO
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Webull offers kinds of Halozyme Therapeutics, Inc. stock information, including NASDAQ:HALO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HALO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HALO stock methods without spending real money on the virtual paper trading platform.